Tremelimumab

• Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOT… Pending
  2023-508863-59-01 Phase II 2 countries University Health Network
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting
  2025-521639-34-00 Phase I (Other) 1 country AstraZeneca AB
• Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting
  2024-513219-29-00 Phase III 2 countries University College London
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin… Recruiting
  2024-518210-81-00 Phase III 6 countries AstraZeneca AB
• TransBronchial Needle injection of Tremelimumab in early-stage NSCLC patients (TALENT) Recruiting
  2024-511878-67-00 Phase I/II 1 country Amsterdam UMC Stichting
• Durvalumab and tremelimumab with or without Hepatic Arterial Infusion of gemcitabine and oxaliplatin in hepatocellular carcinoma patients. Recruiting
  2024-514912-28-00 Phase II/III 1 country Unicancer
• MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER” Recruiting
  2023-508201-25-00 Phase II 1 country Centre De Lutte Contre Le Cancer Eugene Marquis
• First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran… Recruiting
  2023-503326-39-00 Phase III 1 country Institut Gustave Roussy
• Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga… Recruiting
  2023-504600-28-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
• DUMELEP trial - Durvalumab (MEDI4736)/Tremelimumab in neoadjuvant and adjuvant setting in patients with HCC treated by percutaneous ablation… Recruiting
  2024-515768-30-01 Phase II 1 country Assistance Publique Hopitaux De Paris
• Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer Recruiting
  2024-515127-11-00 Phase II 2 countries Klinikum der Universitaet Muenchen AöR
• Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanc… Recruiting
  2024-518656-23-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• IMMUWIN - A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage… Recruiting
  2024-513950-32-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• A clinical study to evaluate the safety, tolerability and early efficacy of the study drug (Durvalumab) alone and a combination of study dru… Recruiting
  2023-510424-68-00 Phase I/II 1 country AstraZeneca AB
• MOST Plus (My Own Specific Treatment) - A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of… Recruiting
  2023-510566-27-00 Phase II 1 country Centre Leon Berard
• Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant Mesothelioma Recruiting
  2024-511841-20-00 Phase II 1 country AstraZeneca AB
• Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric… Ended
  2024-518842-26-00 Phase II 1 country Fondazione GONO G.I.
• Study Title: Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without Tremelimumab in MSS … Ended
  2023-509619-10-00 Phase II 1 country Vall D Hebron Institute Of Oncology
• ETOP 14-18 CHESS: Immunotherapy, chemotherapy and radiotherapy, followed by surgery or radiotherapy, for patients with newly diagnosed non-s… Ended
  2024-511134-12-00 Phase II 3 countries ETOP IBCSG Partners Foundation
• A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T… Ended
  2023-508945-41-00 Phase II 3 countries Biocompatibles UK Limited
• SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended
  2022-502012-37-00 Phase III 4 countries AstraZeneca AB
• Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) pati… Ended
  2024-511439-84-00 Phase II 2 countries Klinikum der Universitaet Muenchen AöR
• A global study to evaluate transarterial chemoembolization(TACE) in combination with durvalumab, tremelimumab +/-lenvatinib therapy compared… Ended
  2023-508701-24-00 Phase III 6 countries AstraZeneca AB
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended
  2023-507342-84-00 Phase III 9 countries Astrazeneca AB

Showing 1–24 of 35 trials